• Tocagen inks commercialisation deal with ApolloBio biospectrumasia
    April 23, 2018
    Under the terms of the deal, Tocagen will receive $16M upfront, $4M in near-term milestones, up to $111M in future milestones and tiered low double-digit royalties on net sales.
PharmaSources Customer Service